1. Scrip
  2. >>Therapy Areas

Allergan's Assets Could Diversify Pfizer's Neurology Portfolio

 
• By Mandy Jackson

If Pfizer Inc. were to buy Allergan plc – or vice versa – the merged companies would have a large and actually quite diverse portfolio of drugs for central nervous system (CNS) diseases and conditions.

If Pfizer Inc. were to buy Allergan plc – or vice versa – the merged companies would have a large and actually quite diverse portfolio of drugs for central nervous system (CNS) diseases and conditions.

Both pharmaceutical firms disclosed in late October that they're in friendly negotiations about a transaction between the companies, though Allergan...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Musculoskeletal

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.